Mochi Health review

Mochi Health: the $60 on the front page is well under half the bill

Mochi advertises compounded semaglutide from $60 a month, and that figure is true — at the lowest weekly dose. It is also only one of the two charges. The clinic itself costs $79 a month, and Mochi says so in a single unambiguous line on its own weight-loss page: medications and diagnostic services are not included in the membership. Add the two together and a month starts at $139 for semaglutide and $169 for tirzepatide. The drug charge then rises with the dose, so the higher doses land between about $161 and $268 all-in for semaglutide and up to $278 for tirzepatide. The first month of the clinic charge is discounted for new members, which makes month one look cheaper than every month after it.

We are being precise about this because the two-part structure is the single most common way a family budget gets ambushed in this market, and because Mochi, to its credit, is not hiding it. The disclosure is right there. It is just printed next to a $60 that is set in much larger type.

What the money actually buys

• Compounded semaglutide: from $139/month all-in — $79 clinic plus $60 to $189 for the drug, depending on the weekly dose
• Compounded tirzepatide: from $169/month all-in — $79 clinic plus $90 to $199 for the drug, depending on the weekly dose
• First month: the clinic charge is discounted for new members, and the discount does not repeat
• Paid ahead: $207 for three months of clinic access, $354 for six, $588 for twelve — the drug charge is unchanged either way
• Not included in the clinic fee: the medication and any diagnostics; Zepbound is listed from $299 for the medication alone

The clinical bench is the reason to look twice

Most of the compounded field on our list is anonymous. You fill in a form, someone with a license approves it, and you never learn a name. Mochi does the opposite: it lists nine clinicians with credentials attached — Roberto Valledor MD, Leah Jones MD, Clete Barrick MD, Amisa Patel DO and Amber Patel DO among them, carrying obesity-medicine board certification between them, plus a pediatrician, a nurse practitioner and two registered dietitians. Then it puts a 30-minute video visit with the provider you pick in front of the prescription. Not an asynchronous review. An appointment, with a person, who has trained in the specific medicine you are asking about.

For a mother that cuts both ways, and it is worth being honest about the second edge. Thirty minutes on video with an obesity-medicine physician is a genuinely better standard of care than a questionnaire, and it is the kind of thing that catches a thyroid history or a pregnancy plan that a form would sail past. It is also thirty minutes you have to find, at a time you have to agree to, which is the scarcest currency a mother has. If asynchronous is the only way a program fits your week, that is a real constraint and not a preference.

The gap in the disclosure, and the two companies in court

For all the names Mochi publishes, one is missing: the pharmacy. Its terms refer only to "certain third party pharmacies" and its pharmacy page describes a marketplace that patients and providers choose from, without naming a single one. For a compounded medication — a preparation that is not an FDA-approved finished product the way Wegovy and Zepbound are — the compounder's identity is the disclosure that matters most, and it is the one you cannot check. Providers like Trimi Health name theirs. Mochi does not.

The second thing to know is that both manufacturers have taken Mochi to federal court over its compounded line. Eli Lilly filed in the Northern District of California in April 2025 and Novo Nordisk followed in August 2025; a consumer class action was filed in the same court in February 2026. All three are pending, and an allegation is not a finding — plenty of telehealth compounders are facing near-identical suits as the shortage-era compounding window closes. But it is the kind of fact you would rather learn now than from a letter telling you your prescription has stopped.

What it does not offer a mother

Nothing maternal, and this is where a strong clinical program still reads as a general one. There is no postpartum guidance, no breastfeeding guidance and no PCOS pathway anywhere on the site; menopause and hormone therapy exist, but as a separate vertical you buy separately. As with every GLP-1, none of this is for use during pregnancy or while breastfeeding, and every label says so. What Mochi gives you is an obesity-medicine physician on a video call who is qualified to have that timing conversation — you will simply have to raise it yourself, because the site never will. Our guide on what to tell your OB before starting a GLP-1 is the conversation to have first.

The bottom line

Mochi Health is a better-run program than its pricing presentation suggests, and a more expensive one. Budget $139 and up as the dose climbs, not $60, and you are buying a named, board-certified clinician and a real appointment for roughly the market rate — which is a fair trade, and rare. Hold against it the unnamed pharmacy and two manufacturers in court. If what you want instead is one number that is the whole number, with a prescriber who raises pregnancy and weaning without being asked, CoreAge Rx, a featured partner, is the cleaner fit — you can put the two side by side in our head-to-head or against the field in the best GLP-1 for moms ranking.